Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Phase 3 human trials of Oxford coronavirus vaccine © John Cairns
  • Researchers show overall vaccine efficacy of 70.4% from a pooled analysis of two-dose regimen
  • No hospitalisations or severe disease observed in the vaccinated groups from three weeks after first dose
  • Efficacy results are based on data taken from 11,636 volunteers across the United Kingdom and Brazil
  • Data are first Phase 3 trial results of a coronavirus vaccine to be published in peer-review literature

The new study published in the Lancet is the first peer-reviewed publication of phase 3 data from studies of a vaccine against the coronavirus. 

The efficacy data are based on 11,636 volunteers across the United Kingdom and Brazil, and combined across three groups of people vaccinated – two groups who received a standard dose prime vaccination followed by a standard dose booster vaccination and one group (in the UK only) who received a low dose prime vaccination followed by a standard dose vaccination.

The full story is available on the University of Oxford website

Similar stories

Read the latest issue of JNDS

A new issue of Journal of the Nuffield Department of Surgical Sciences (JNDS) is out now.

Genetic mapping of tumours reveals how cancers grow

Researchers from the University of Oxford, KTH Royal Institute of Technology, Science for Life Laboratory, and the Karolinska Institutet, Solna, Sweden, have found that individual prostate tumours contain a previously unknown range of genetic variation.

Two NDS researchers receive prestigious MRC Clinical Research Training Fellowships

Miss Catherine Lovegrove and Dr Alexander Sagar from the Nuffield Department of Surgical Sciences (NDS) have been awarded highly competitive Clinical Research Training Fellowships by the Medical Research Council (MRC).

Blog posts

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.

Lights, camera, action! My journey into video production

Dr Hannah McGivern provides a 'behind-the-scenes' account of her experience producing the video 'Journey of a QUOD Sample: Donating to Transplant Research', supported by the funds from the University of Oxford Public Engagement with Research (PER) Seed Fund.

Mentoring in practice

NDS has launched a new, interdepartmental mentoring scheme called RECOGNISE. In this podcast, Gemma Horbatowski (HR Advisor) interviews Monica Dolton (Programme Manager and Research Project Manager) about her experiences of mentor-mentee relationships.